PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 140 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2014. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $1,384,000 | -61.0% | 14,000 | -52.8% | 0.00% | -75.0% |
| Q3 2017 | $3,549,000 | +370.7% | 29,632 | +46.3% | 0.01% | +300.0% |
| Q1 2017 | $754,000 | +40.1% | 20,248 | +15.6% | 0.00% | +100.0% |
| Q4 2016 | $538,000 | -55.6% | 17,508 | -3.3% | 0.00% | -66.7% |
| Q3 2016 | $1,213,000 | -88.7% | 18,104 | -60.1% | 0.00% | -85.7% |
| Q1 2015 | $10,704,000 | -20.4% | 45,333 | -36.2% | 0.02% | -25.0% |
| Q4 2014 | $13,453,000 | -20.7% | 71,075 | -0.1% | 0.03% | -22.2% |
| Q3 2014 | $16,967,000 | +288.3% | 71,118 | +7.4% | 0.04% | +300.0% |
| Q2 2014 | $4,369,000 | -33.9% | 66,188 | +4.3% | 0.01% | -40.0% |
| Q1 2014 | $6,612,000 | -27.4% | 63,488 | -27.9% | 0.02% | -31.8% |
| Q4 2013 | $9,113,000 | +85.8% | 88,026 | -3.7% | 0.02% | +69.2% |
| Q3 2013 | $4,904,000 | +20.9% | 91,388 | 0.0% | 0.01% | +8.3% |
| Q2 2013 | $4,055,000 | – | 91,388 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 1,417,000 | $18,010,000 | 2.24% |
| Palo Alto Investors LP | 1,405,680 | $17,866,000 | 0.87% |
| PFM Health Sciences, LP | 2,838,376 | $36,076,000 | 0.68% |
| TANG CAPITAL MANAGEMENT LLC | 349,400 | $4,441,000 | 0.60% |
| Capital Impact Advisors, LLC | 127,029 | $1,615,000 | 0.59% |
| Leap Investments LP | 29,100 | $370,000 | 0.50% |
| Spark Investment Management LLC | 454,300 | $5,774,000 | 0.40% |
| Partner Investment Management, L.P. | 27,567 | $350,000 | 0.37% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 262,945 | $3,342,000 | 0.26% |
| Rock Springs Capital Management LP | 534,400 | $6,792,000 | 0.25% |